Latest Conference Articles

How CTCL Treatment Strategies Have Changed, Advanced in Recent Years

How CTCL Treatment Strategies Have Changed, Advanced in Recent Years

September 24th 2021, 12:00pm

Society of Hematologic Oncology (SOHO) Annual Meeting

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses how the treatment of advanced cutaneous T cell lymphoma has changed in recent years and whether there have been any advancements of note.

Overview of Recent Key Trials in the CTCL Space

Overview of Recent Key Trials in the CTCL Space

September 23rd 2021, 12:00pm

Society of Hematologic Oncology (SOHO) Annual Meeting

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, provides an overview of key trials that have been conducted in the advanced cutaneous T cell lymphoma space in recent years.

Understanding the Patient Selection Process for CTCL Treatment

Understanding the Patient Selection Process for CTCL Treatment

September 22nd 2021, 12:00pm

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explained whether the current advanced cutaneous T cell lymphoma (CTCL) treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.

Overview of Treatment Approaches in Advanced CTCL

Overview of Treatment Approaches in Advanced CTCL

September 21st 2021, 4:09pm

Society of Hematologic Oncology (SOHO) Annual Meeting

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, described what advanced cutaneous T cell lymphoma is in terms of classification and what current treatment approaches are available.

Latest Treatment Updates in Cervical Cancer

Latest Treatment Updates in Cervical Cancer

September 20th 2021, 1:00pm

ESMO

Pharmacy Times spoke with Dr. Bradley Monk, investigator for KEYNOTE-826, #LBA2, which was presented at the ESMO Congress 2021, about the study and its importance to the world of cervical cancer.

Salvage Therapy for Amyloidosis in Multiple Myeloma: Agents and Anti-Fibril Therapy

Salvage Therapy for Amyloidosis in Multiple Myeloma: Agents and Anti-Fibril Therapy

September 17th 2021, 5:29pm

Society of Hematologic Oncology (SOHO) Annual Meeting

A presentation at the Society of Hematologic Oncology 2021 Annual Meeting reviewed the treatment of amyloidosis in multiple myeloma.

Updates in Sequencing Treatment for Early Multiple Myeloma Relapse

Updates in Sequencing Treatment for Early Multiple Myeloma Relapse

September 15th 2021, 7:42pm

Society of Hematologic Oncology (SOHO) Annual Meeting

Presenter Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca-IBSAL, Salamanca, Spain, discussed how optimal sequencing in MM has changed from those outlined in the older EU guidelines.

Balancing Toxicity, Tolerability, Efficacy Is Essential for CAR T-Cell Therapies in Indolent B-Cell Lymphoma

Balancing Toxicity, Tolerability, Efficacy Is Essential for CAR T-Cell Therapies in Indolent B-Cell Lymphoma

September 10th 2021, 6:53pm

Society of Hematologic Oncology (SOHO) Annual Meeting

With CAR T-cell therapies showing promise for follicular lymphoma and marginal zone lymphoma, clinicians must weigh toxicity and tolerability almost as strongly as efficacy because patients can live years with these diseases

Investigational BTK Inhibitor Shows Promise in Chronic, Small Lymphocytic Leukemia

Investigational BTK Inhibitor Shows Promise in Chronic, Small Lymphocytic Leukemia

September 9th 2021, 8:10pm

Society of Hematologic Oncology (SOHO) Annual Meeting

The efficacy of pirtobrutinib does not depend on prior therapy, reason for prior BTK inhibitor discontinuation, or C481 mutation status, according to the presentation.

Understanding and Overcoming Toxicities in Asparaginase Treatment for ALL

Understanding and Overcoming Toxicities in Asparaginase Treatment for ALL

September 9th 2021, 4:50pm

Society of Hematologic Oncology (SOHO) Annual Meeting

Because asparaginase is used exclusively in ALL, most adult oncologists do not administer it routinely.